With the notable exception of gastrointestinal stromal tumor which is predominantly driven by gain-of-function mutations in the genes encoding KIT or PDGFRA receptor tyrosine kinases [10,11], it is challenging to design a ctDNA assay in sarcoma dependent on recurrent SNVs. This evidence concerns the gene NTRK1 and sarcoma.